Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader

Rhea-AI Summary

Kelyniam Global (OTC:KLYG) will present at Planet MicroCap Las Vegas 2026 on June 17, 2026, at 4:30 PM PST at the Bellagio.

The company will highlight its Fusion™ BCP-PEEK implant, regenerative product portfolio, Q1 2026 revenue of $1.15 million (+84% YoY), and growth strategy.

News Market Reaction – KLYG

+5.94%

+5.94% Session close to close

In the Jun 1 session, KLYG gained 5.94%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

COLLINSVILLE, Conn., June 1, 2026 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leader in patient-specific cranial and craniofacial implants, today announced it will present at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026 at 4:30 PM PST at the Bellagio Resort & Hotel.

Kelyniam CEO Ross Bjella will deliver the company presentation followed by a live Q&A. A webcast will be available here. Investors interested in 1x1 meetings should register at the conference site. The Webcast Link is: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpUua92/FJagJ5MsSrKYWC7zLA58iq

"Kelyniam is hitting this conference for the first time," said Ross Bjella, Chairman and CEO. "We've proudly evolved from a single-product PEEK company into the clear leader in regenerative neurosurgery. With a growing suite of advanced biomaterials that actively promote bone integration, strong Q1 momentum, and an exciting pipeline, we're delivering better outcomes for surgeons and patients while building real shareholder value."

Key Highlights:

• Fusion™ Implant Launch: FDA-cleared BCP-PEEK implant – the first new material approved in the U.S. cranial market in eight years, combining strength with superior bone integration and 24-48 hour delivery.  The first implant was delivered in April.
• Regenerative Leadership: The only company offering neurosurgeons a full portfolio including Fusion™ BCP-PEEK, CustomizedBone™ hydroxyapatite (the only pediatric option for children as young as seven), and Osteopore polycaprolactone products.
• Financial Momentum: Q1 2026 revenue of $1.15 million (+84% YoY), gross profit +105%, and operating income of $295,295.
• Strategic Acceleration: Expanded licensing agreements, new development partnerships, and the addition of veteran medical device leader Kris Renton as Chief Revenue Officer.

The presentation will showcase Kelyniam's differentiated regenerative platform, rapid manufacturing edge, and clear path to sustained growth in the expanding cranial reconstruction market.

About Kelyniam Global, Inc. Kelyniam Global, Inc. (OTC: KLYG) specializes in the rapid production of patient-specific cranial and craniofacial implants using advanced CAD/CAM technology and next-generation biomaterials. Renowned for industry-leading 24-48 hour turnaround, Kelyniam partners with neurosurgeons to deliver superior clinical and economic outcomes. For more information, visit www.kelyniam.com.

Cautionary Note Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties. Please refer to Kelyniam's SEC filings for more details.

View original content:https://www.prnewswire.com/news-releases/kelyniam-global-to-present-at-planet-microcap-las-vegas-2026--from-single-product-to-regenerative-medicine-leader-302786273.html

SOURCE Kelyniam Global Inc

FAQ

When will Kelyniam Global (OTC:KLYG) present at Planet MicroCap Las Vegas 2026?

Kelyniam Global will present on June 17, 2026, at 4:30 PM PST at the Bellagio Resort. According to Kelyniam, CEO Ross Bjella will lead the presentation, followed by a live Q&A and an accessible webcast for investors.

How can investors watch Kelyniam Global's Planet MicroCap Las Vegas 2026 webcast?

Investors can watch Kelyniam Global’s conference presentation via a dedicated webcast link provided by the company. According to Kelyniam, the webcast is publicly accessible, and investors seeking 1x1 meetings should register through the official Planet MicroCap conference site.

What Q1 2026 financial results will Kelyniam Global (OTC:KLYG) highlight at Planet MicroCap?

Kelyniam plans to highlight Q1 2026 revenue of $1.15 million, up 84% year over year. According to Kelyniam, gross profit grew 105%, and operating income reached $295,295, supporting its message of financial and operational momentum in cranial reconstruction.

What is Kelyniam Global's Fusion BCP-PEEK implant and why is it important?

Fusion is an FDA-cleared BCP-PEEK cranial implant combining PEEK strength with enhanced bone integration and 24–48 hour delivery. According to Kelyniam, it is the first new material approved in the U.S. cranial market in eight years, with first delivery in April 2026.

How is Kelyniam Global positioning itself as a regenerative neurosurgery leader?

Kelyniam emphasizes a full regenerative portfolio featuring Fusion BCP-PEEK, CustomizedBone hydroxyapatite, and Osteopore polycaprolactone products. According to Kelyniam, this offers neurosurgeons options from pediatric cases to complex reconstruction, supporting its claim of leadership in regenerative neurosurgery solutions.

What strategic initiatives will Kelyniam Global discuss at Planet MicroCap 2026?

Kelyniam will discuss expanded licensing agreements, new development partnerships, and adding Kris Renton as Chief Revenue Officer. According to Kelyniam, these actions are intended to accelerate commercialization of its regenerative platform and support a clear path to sustained growth in cranial reconstruction.